 | ENDOCRINE HYPERTENSION
Copyright © 2002 by the New York Academy of Sciences
description
Annals of the New York Academy of Sciences 970:119-133 (2002)
© 2002 New York Academy of Sciences
The Medical Management of Cushing's Syndrome
DAMIAN MORRIS AND
ASHLEY GROSSMAN
Department of Endocrinology, St. Bartholomew's Hospital, London EC1A 7BE, England, United Kingdom
Address for correspondence: Ashley Grossman, B.A., B.Sc., M.D., FRCP, FMedSci, Professor of Neuroendocrinology, Department of Endocrinology, St. Bartholomew's Hospital, London EC1A 7BE, Great Britain. Voice: +44-(0)20-7601-8343; fax: +44-(0)20-7601-8505.
A.B.Grossman{at}qmul.ac.uk
Ann. N.Y. Acad. Sci. 970: 119-133 (2002).
Cushing's syndrome results from prolonged exposure to excessive circulating glucocorticosteroids, and is associated with significant morbidity and mortality. While the treatment of choice in most patients is surgical, the metabolic consequences of the syndrome, including increased tissue fragility, poor wound healing, hypertension, and diabetes mellitus, increase the risks of such surgery. The hypercortisolemia and its sequelae can be efficiently reversed using medical therapy, either as a temporary measure prior to definitive treatment, or longer term in more difficult cases. Drug treatment has been targeted at the hypothalamic/pituitary level, the adrenal glands, and also at the glucocorticoid receptor level. In this review we discuss the pharmacotherapeutic agents that have been used in Cushing's syndrome, and their efficacy, the monitoring of treatment, and potential therapies that may prove useful in the future in this complex endocrinological disorder.
Key Words: Cushing's syndrome • drug therapy • steroid biosynthesis inhibitors • 5-HT antagonists • dopamine agonists • somatostatin analogues • GABA agonists • glucocorticoid antagonists
This article has been cited by other articles:
|
|
|
|
 
T. Tateno, H. Izumiyama, M. Doi, T. Yoshimoto, M. Shichiri, N. Inoshita, K. Oyama, S. Yamada, and Y. Hirata
Differential gene expression in ACTH -secreting and non-functioning pituitary tumors
Eur. J. Endocrinol.,
December 1, 2007;
157(6):
717 - 724.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. L. Batista, X. Zhang, R. Gejman, P. J. Ansell, Y. Zhou, S. A. Johnson, B. Swearingen, E. T. Hedley-Whyte, C. A. Stratakis, and A. Klibanski
The Effects of SOM230 on Cell Proliferation and Adrenocorticotropin Secretion in Human Corticotroph Pituitary Adenomas
J. Clin. Endocrinol. Metab.,
November 1, 2006;
91(11):
4482 - 4488.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Castillo, D. Giacomini, M. Paez-Pereda, J. Stalla, M. Labeur, M. Theodoropoulou, F. Holsboer, A. B. Grossman, G. K. Stalla, and E. Arzt
Retinoic Acid as a Novel Medical Therapy for Cushing's Disease in Dogs
Endocrinology,
September 1, 2006;
147(9):
4438 - 4444.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Riedl, C. Maier, G. Zettinig, P. Nowotny, W. Schima, and A. Luger
Long term control of hypercortisolism with fluconazole: case report and in vitro studies.
Eur. J. Endocrinol.,
April 1, 2006;
154(4):
519 - 524.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Nigawara, Y. Iwasaki, M. Asai, M. Yoshida, M. Kambayashi, H. Sashinami, K. Hashimoto, and T. Suda
Inhibition of 11{beta}-Hydroxysteroid Dehydrogenase Eliminates Impaired Glucocorticoid Suppression and Induces Apoptosis in Corticotroph Tumor Cells
Endocrinology,
February 1, 2006;
147(2):
769 - 772.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. van der Hoek, M. Waaijers, P. M. van Koetsveld, D. Sprij-Mooij, R. A. Feelders, H. A. Schmid, P. Schoeffter, D. Hoyer, D. Cervia, J. E. Taylor, et al.
Distinct functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumor cells
Am J Physiol Endocrinol Metab,
August 1, 2005;
289(2):
E278 - E287.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. J Hofland, J. van der Hoek, R. Feelders, M. O van Aken, P. M van Koetsveld, M. Waaijers, D. Sprij-Mooij, C. Bruns, G. Weckbecker, W. W de Herder, et al.
The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5
Eur. J. Endocrinol.,
April 1, 2005;
152(4):
645 - 654.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
